Endocrinology and metabolism clinics of North AmericaJul 29, 2026

Using GLP-1 Receptor Agonists and SGLT Inhibitors Together in Type 1 Diabetes: Reasons, Timing, and Clinical Uses

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Aug 3, 2026

Abstract

Adjunct therapy may help improve glycemic management in people with type 1 diabetes.

Many individuals with type 1 diabetes struggle to reach target glycemic levels despite advanced insulin treatments.
Adjunct therapies aim to lower hemoglobin A1c (HbA1c) and improve health outcomes, including weight management.
Incretin-based therapies and SGLT-1/2 inhibitors are currently used off-label for type 1 diabetes.
These therapies could offer a promising approach for better glycemic control and additional health benefits.

Simplified

Even with the most advanced insulin preparations and delivery systems currently available, it is challenging for many people with type 1 diabetes (T1D) to achieve target levels of glycemic management. Adjunct therapy in T1D consists of adding glucose-lowering agents besides insulin with the aim of lowering hemoglobin A1c (HbA1c) and improving other health outcomes, including weight. It is an attractive potential strategy for achieving glycemic targets and other benefits in this T1D subpopulation. While not yet Food and Drug Adminstration (FDA)-approved for this use, incretin-based therapies (glucagon-like peptide-1 receptor agonist-based therapy) and sodium-glucose cotransporter-1/2 (SGLT-1/2) inhibitors are being prescribed off-label for T1D.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

Disclosure H. Ghanim: Nothing to disclose; S.R. Srungavarapu: Nothing to disclose. A. Chaudhuri: Consultant, research support and speaker for Lilly and Novo. P. Dandona: Research funding from BreakthroughT1D: 3SRA2019669MB

PubMed

Using GLP-1 Receptor Agonists and SGLT Inhibitors Together in Type 1 Diabetes: Reasons, Timing, and Clinical Uses

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief